Eli Lilly and Company (LLY)
USD 764.71
(-1.79%)
USD 764.71
(-1.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.56 Billion USD | 32.03% |
| 2022 | 8.66 Billion USD | 7.95% |
| 2021 | 8.04 Billion USD | 14.37% |
| 2020 | 8.91 Billion USD | 15.69% |
| 2019 | 6.89 Billion USD | -31.52% |
| 2018 | 5.53 Billion USD | 24.98% |
| 2017 | 3.98 Billion USD | 80.15% |
| 2016 | 5.05 Billion USD | -4.69% |
| 2015 | 4.37 Billion USD | 12.44% |
| 2014 | 4.52 Billion USD | -23.57% |
| 2013 | 7.49 Billion USD | 16.01% |
| 2012 | 7.04 Billion USD | -37.21% |
| 2011 | 6.9 Billion USD | -11.92% |
| 2010 | 8.03 Billion USD | 5.29% |
| 2009 | 6.91 Billion USD | -42.51% |
| 2008 | 43.3 Million USD | 98.8% |
| 2007 | 5.85 Billion USD | 17.73% |
| 2006 | 4.45 Billion USD | 10.65% |
| 2005 | 4.37 Billion USD | 5.68% |
| 2004 | 4.92 Billion USD | 16.36% |
| 2003 | 4.05 Billion USD | 17.13% |
| 2002 | 3.82 Billion USD | -14.35% |
| 2001 | 4.18 Billion USD | 19.97% |
| 2000 | 3.99 Billion USD | -5.98% |
| 1999 | 3.8 Billion USD | 13.51% |
| 1998 | 3.31 Billion USD | -29.67% |
| 1997 | 2.94 Billion USD | 102.08% |
| 1996 | 2.58 Billion USD | -6.02% |
| 1995 | 2.53 Billion USD | 6.11% |
| 1994 | 2.22 Billion USD | 131.97% |
| 1993 | 1.05 Billion USD | -33.08% |
| 1992 | 1.52 Billion USD | -23.51% |
| 1991 | 2.06 Billion USD | 15.72% |
| 1990 | 1.78 Billion USD | 28.18% |
| 1989 | 1.39 Billion USD | 11.46% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 2.24 Billion USD | -45.38% |
| 2024 Q2 | 4.71 Billion USD | 32.05% |
| 2024 Q1 | 3.21 Billion USD | 2.69% |
| 2023 Q1 | 1.7 Billion USD | -28.79% |
| 2023 Q2 | 2.31 Billion USD | 36.14% |
| 2023 FY | - USD | 32.03% |
| 2023 Q3 | 6.4 Billion USD | 175.9% |
| 2023 Q4 | 3.6 Billion USD | -43.7% |
| 2022 FY | - USD | 7.95% |
| 2022 Q3 | 2.4 Billion USD | 15.47% |
| 2022 Q4 | 2.39 Billion USD | -0.39% |
| 2022 Q1 | 2.73 Billion USD | -5.0% |
| 2022 Q2 | 2.08 Billion USD | -23.95% |
| 2021 Q2 | 1.85 Billion USD | -14.58% |
| 2021 Q3 | 2.22 Billion USD | 19.87% |
| 2021 Q4 | 2.87 Billion USD | 29.17% |
| 2021 FY | - USD | 14.37% |
| 2021 Q1 | 2.17 Billion USD | -18.29% |
| 2020 Q4 | 2.66 Billion USD | 79.9% |
| 2020 Q1 | 1.81 Billion USD | 6.55% |
| 2020 Q2 | 1.68 Billion USD | -7.43% |
| 2020 FY | - USD | 15.69% |
| 2020 Q3 | 1.48 Billion USD | -11.86% |
| 2019 Q4 | 1.7 Billion USD | 7.41% |
| 2019 Q1 | 1.76 Billion USD | -16.07% |
| 2019 Q2 | 1.54 Billion USD | -12.36% |
| 2019 FY | - USD | -31.52% |
| 2019 Q3 | 1.58 Billion USD | 2.44% |
| 2018 FY | - USD | 24.98% |
| 2018 Q2 | 3.36 Billion USD | 67.95% |
| 2018 Q3 | 2 Billion USD | -40.28% |
| 2018 Q1 | 2 Billion USD | -14.22% |
| 2018 Q4 | 2.1 Billion USD | 4.77% |
| 2017 Q2 | 1.36 Billion USD | -37.67% |
| 2017 Q4 | 2.33 Billion USD | 27.72% |
| 2017 FY | - USD | 80.15% |
| 2017 Q1 | 2.18 Billion USD | 77.77% |
| 2017 Q3 | 1.82 Billion USD | 34.01% |
| 2016 Q4 | 1.23 Billion USD | 19.03% |
| 2016 Q2 | 1.03 Billion USD | 6.2% |
| 2016 Q3 | 1.03 Billion USD | -0.46% |
| 2016 FY | - USD | -4.69% |
| 2016 Q1 | 978.6 Million USD | -10.03% |
| 2015 Q4 | 1.08 Billion USD | 3.98% |
| 2015 FY | - USD | 12.44% |
| 2015 Q1 | 1.25 Billion USD | -9.76% |
| 2015 Q2 | 1.1 Billion USD | -11.6% |
| 2015 Q3 | 1.04 Billion USD | -5.57% |
| 2014 Q2 | 886.6 Million USD | -1.23% |
| 2014 FY | - USD | -23.57% |
| 2014 Q1 | 897.6 Million USD | -17.33% |
| 2014 Q3 | 824.6 Million USD | -6.99% |
| 2014 Q4 | 1.38 Billion USD | 68.42% |
| 2013 Q3 | 1.54 Billion USD | -5.23% |
| 2013 Q4 | 1.08 Billion USD | -29.71% |
| 2013 FY | - USD | 16.01% |
| 2013 Q1 | 969.9 Million USD | -34.13% |
| 2013 Q2 | 1.63 Billion USD | 68.06% |
| 2012 Q2 | 1.2 Billion USD | -17.41% |
| 2012 Q4 | 1.47 Billion USD | 346.59% |
| 2012 Q3 | 329.7 Million USD | -72.58% |
| 2012 Q1 | 1.45 Billion USD | 3.61% |
| 2012 FY | - USD | -37.21% |
| 2011 Q1 | 2.19 Billion USD | 16.7% |
| 2011 Q3 | 1.61 Billion USD | -14.48% |
| 2011 Q4 | 1.4 Billion USD | -12.79% |
| 2011 Q2 | 1.88 Billion USD | -14.16% |
| 2011 FY | - USD | -11.92% |
| 2010 FY | - USD | 5.29% |
| 2010 Q3 | 2.11 Billion USD | -1.18% |
| 2010 Q4 | 1.88 Billion USD | -11.02% |
| 2010 Q1 | 2.01 Billion USD | 17.24% |
| 2010 Q2 | 2.13 Billion USD | 5.91% |
| 2009 Q4 | 1.72 Billion USD | -14.35% |
| 2009 Q2 | 1.47 Billion USD | -29.57% |
| 2009 Q3 | 2.01 Billion USD | 36.77% |
| 2009 Q1 | 2.08 Billion USD | -68.41% |
| 2009 FY | - USD | -42.51% |
| 2008 Q1 | 1.75 Billion USD | 7.33% |
| 2008 Q3 | 3.42 Billion USD | 104.66% |
| 2008 Q2 | 1.67 Billion USD | -4.52% |
| 2008 Q4 | 6.6 Billion USD | 92.68% |
| 2008 FY | - USD | 98.8% |
| 2007 Q4 | 1.63 Billion USD | 8.96% |
| 2007 FY | - USD | 17.73% |
| 2007 Q1 | 1.8 Billion USD | -15.04% |
| 2007 Q2 | 1.83 Billion USD | 1.51% |
| 2007 Q3 | 1.5 Billion USD | -18.13% |
| 2006 FY | - USD | 10.65% |
| 2006 Q4 | 2.12 Billion USD | 71.88% |
| 2006 Q3 | 1.23 Billion USD | 6.75% |
| 2006 Q2 | 1.15 Billion USD | -2.81% |
| 2006 Q1 | 1.19 Billion USD | -4.56% |
| 2005 Q2 | 2.06 Billion USD | 134.04% |
| 2005 Q3 | 1 Billion USD | -51.12% |
| 2005 Q4 | 1.24 Billion USD | 23.89% |
| 2005 FY | - USD | 5.68% |
| 2005 Q1 | 881.3 Million USD | -43.15% |
| 2004 Q1 | 1.35 Billion USD | 48.2% |
| 2004 Q3 | 903.7 Million USD | -18.97% |
| 2004 Q4 | 1.55 Billion USD | 71.54% |
| 2004 FY | - USD | 16.36% |
| 2004 Q2 | 1.11 Billion USD | -17.52% |
| 2003 Q2 | 1 Billion USD | -25.58% |
| 2003 Q1 | 968.6 Million USD | 39.9% |
| 2003 Q3 | 1.08 Billion USD | 12.96% |
| 2003 Q4 | 996.4 Million USD | -15.42% |
| 2003 FY | - USD | 17.13% |
| 2002 Q1 | 882.3 Million USD | -8.49% |
| 2002 Q4 | 992.4 Million USD | -11.34% |
| 2002 Q3 | 1.02 Billion USD | 22.8% |
| 2002 FY | - USD | -14.35% |
| 2002 Q2 | 920.9 Million USD | 3.12% |
| 2001 Q1 | 1.11 Billion USD | 16.82% |
| 2001 Q4 | 867.2 Million USD | -23.0% |
| 2001 FY | - USD | 19.97% |
| 2001 Q3 | 1.02 Billion USD | 3.39% |
| 2001 Q2 | 1.17 Billion USD | 7.55% |
| 2000 Q3 | 1.13 Billion USD | 27.27% |
| 2000 Q1 | 911.8 Million USD | -33.78% |
| 2000 FY | - USD | -5.98% |
| 2000 Q2 | 946.8 Million USD | 36.78% |
| 2000 Q4 | 999 Million USD | -19.65% |
| 1999 Q1 | 868.5 Million USD | 43.5% |
| 1999 Q3 | 1.01 Billion USD | 14.25% |
| 1999 Q4 | 1.06 Billion USD | 4.03% |
| 1999 FY | - USD | 13.51% |
| 1999 Q2 | 852.4 Million USD | -21.83% |
| 1998 Q4 | 794.2 Million USD | -29.75% |
| 1998 Q3 | 878.6 Million USD | 46.44% |
| 1998 Q2 | 739.5 Million USD | -16.24% |
| 1998 Q1 | 842.5 Million USD | 15.71% |
| 1998 FY | - USD | -29.67% |
| 1997 Q4 | 749.3 Million USD | -1.32% |
| 1997 Q1 | 777.8 Million USD | 17.07% |
| 1997 Q2 | 676.5 Million USD | 213.58% |
| 1997 Q3 | 764.5 Million USD | -69.94% |
| 1997 FY | - USD | 102.08% |
| 1996 Q3 | 673.1 Million USD | 20.92% |
| 1996 Q4 | 678.2 Million USD | 15.4% |
| 1996 FY | - USD | -6.02% |
| 1996 Q1 | 662 Million USD | -1.65% |
| 1996 Q2 | 577 Million USD | -20.18% |
| 1995 Q4 | 588.7 Million USD | -5.45% |
| 1995 FY | - USD | 6.11% |
| 1995 Q3 | 648 Million USD | 17.37% |
| 1995 Q2 | 597.8 Million USD | -18.01% |
| 1995 Q1 | 701 Million USD | 113.76% |
| 1994 Q4 | 278.5 Million USD | -46.3% |
| 1994 Q1 | 517.8 Million USD | 177.48% |
| 1994 FY | - USD | 131.97% |
| 1994 Q2 | 444.2 Million USD | -19.66% |
| 1994 Q3 | 523.5 Million USD | 30.95% |
| 1993 Q3 | 408.6 Million USD | -3.06% |
| 1993 Q2 | 421.5 Million USD | -13.41% |
| 1993 Q1 | 486.8 Million USD | 9.12% |
| 1993 FY | - USD | -33.08% |
| 1993 Q4 | -713.6 Million USD | -274.65% |
| 1992 Q1 | 523.3 Million USD | 24.33% |
| 1992 Q3 | -229.2 Million USD | -159.0% |
| 1992 Q2 | 388.5 Million USD | -25.76% |
| 1992 FY | - USD | -23.51% |
| 1992 Q4 | 445.3 Million USD | 294.63% |
| 1991 FY | - USD | 13.29% |
| 1991 Q3 | 393 Million USD | -3.46% |
| 1991 Q2 | 407.1 Million USD | -6.71% |
| 1991 Q4 | 420.9 Million USD | 7.1% |
| 1991 Q1 | 436.4 Million USD | 6.83% |
| 1990 FY | - USD | 40.55% |
| 1990 Q2 | 326 Million USD | -13.48% |
| 1990 Q4 | 385.3 Million USD | 10.85% |
| 1990 Q1 | 376.8 Million USD | 194.84% |
| 1990 Q3 | 366.4 Million USD | 13.04% |
| 1989 FY | - USD | 3.99% |
| 1989 Q1 | 1.22 Billion USD | 161.85% |
| 1989 Q3 | 199.9 Million USD | -29.88% |
| 1989 Q2 | 285.1 Million USD | -76.73% |
| 1989 Q4 | 127.8 Million USD | -36.07% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbbVie Inc. | 26.35 Billion USD | 67.494% |
| Bristol-Myers Squibb Company | 19.41 Billion USD | 55.875% |
| Bristol-Myers Squibb Company Ce | 19.41 Billion USD | 55.875% |
| Johnson & Johnson | 23.72 Billion USD | 63.887% |
| Merck & Co., Inc. | 6.9 Billion USD | -24.045% |
| Novartis AG | 18.28 Billion USD | 53.146% |
| Organon & Co. | 1.43 Billion USD | -496.643% |
| Pfizer Inc. | 9.55 Billion USD | 10.351% |